Agile Therapeutics

The Company is focused in the development and commercialization of prescription contraceptive products. The Company has developed a transdermal patch technology, called Skinfusion. The Company's lead product candidate is Twirla, also known as AG200-15, is a combined hormonal contraceptive (CHC) patch. In addition to Twirla, the Company is developing a pipeline of other new transdermal contraceptive products, including AG200-ER, which is a regimen designed to allow a woman to extend the length of her cycle; AG200-SP, which is a regimen designed to provide a shortened hormone-free interval, and AG890, which is a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. Each of its product candidates utilizes its Skinfusion technology designed to deliver contraceptive-levels of hormones to the blood stream through the skin over a seven-day period.
Type
Public
HQ
Princeton, US
Founded
1997
Employees
17 (est)
Agile Therapeutics was founded in 1997 and is headquartered in Princeton, US

Key People at Agile Therapeutics

Gracelyn S.Deebo

Gracelyn S.Deebo

Senior Vice President, Regulatory Affairs
Scott Coiante

Scott Coiante

Chief Financial Officer
C.Gregory Arnold

C.Gregory Arnold

Vice President of Manufacturing
Al Altomari

Al Altomari

President & CEO & Board ofDirectors
Robert G.Conway

Robert G.Conway

Chief Development Officer, Vice President, Operations
Marie Foegh

Marie Foegh

Chief Medical Officer, Vice President, Clinical Research and Development

Agile Therapeutics Locations

Princeton, US

Agile Therapeutics Metrics

Agile Therapeutics Summary

Market capitalization

$197 M

Closing share price

$6.85
Agile Therapeutics's latest market capitalization is $197 M.

Agile Therapeutics Market Value History

Agile Therapeutics News

Agile Therapeutics Company Life

You may also be interested in